Skip to main content

Table 1 Baseline Characteristics of Single lung transplant subjects

From: Differences in airway microbiome and metabolome of single lung transplant recipients

S.
No
AgeGenderSide of TransplantDuration of Transplant (months)Pre-transplant diagnosisISProphylactic AntibioticBAL CultureBAL cell count differentialCLAD at sample collection
(Y/N)
CLAD at follow-up (2 years)
(Y/N)
164MLeft20IPFTac, Pred, AzaVal, Itra, Dapsone,NegativeM-99%, N-1%NN
257MRight13CTD-ILDTac, Pred, MMFTMP/SMX, Val, VoriNegativeM-95%, L-3%, N- 2%YY
364MLeft30IPFTac, Pred, MMFAzithro, TMP/SMX, ValNegativeM-10%, L-40%, N- 50%NY
469MLeft31IPFTac, Pred, AzaDapsone, Azithro,NegativeM-93%, L-5%, N-2%NY
559FRight18IPFTac, Aza PredTMP/SMXNegativeM-38%, L- 54%, N 8%NY
662MLeft79IPFTac, PredDapsone1000 CFU normal floraM-58%, L-3%, N-39%YY
  1. Abbreviations: IS Immunosuppression, Azithro Azithromycin; CLAD Chronic Lung Allograft Dysfunction, IPF Idiopathic pulmonary fibrosis, CTD-ILD Connective tissue disease related interstitial lung disease, Aza Azathioprine, Itra itraconazole, MMF Mycophenolate mofetil, Pred Prednisone, Tac Tacrolimus, TMP/SMX Trimethoprim–sulfamethoxazole, Val Valganciclovir, Vori Voriconazole, M Macrophages, L Lymphocytes, N Neutrophils